Draft future Call topics published online

Tackling cancer through artificial intelligence, antimicrobial resistance, neurodegenerative diseases, rare disease diagnosis, clinical trial data, and patient adherence are the topics proposed for IMI’s next Calls for proposals.
Close up of a hand holding a tiny lightbulb. Credit: Shutterstock

The socio-economic impact of IMI projects

12 years and 150 projects later, what kind of socio-economic impact has IMI-funded research had? Since its inception, IMI has supported 150 different research projects. That’s 150 teams of problem-solvers working together in the spirit of what we like to think of as ‘radical collaboration’. For 12 years, these projects have been producing toolboxes of new technologies, spreading best practices, training, skill-building and sharing not just their knowledge but also...

New tools and trials combat the resurgence of whooping cough

EU-funded researchers hope a greater understanding of interactions between pertussis bacteria and the immune system, together with a toolkit for testing new vaccines, will help prevent whooping cough disease and deaths in babies worldwide.
Pertussis bacteria

COVID-19 is a sign of the times

Repurposing existing drugs could get us out of the current predicament but it’s clear we need to prepare for more pandemics
Novel coronavirus

The secret life of tumours

In recent funding calls, IMI has turned its attention to emerging cancer therapies, seeking better understanding of things like the effect of tumour microenvironment on immunotherapy success
Human colon cancer cells

CANCER-ID hunts for cancer clues in blood samples

Today, many cancer patients have to undergo biopsy surgery to provide doctors with the cell samples they need to diagnose the disease and monitor how well a treatment is working. IMI’s CANCER-ID project has paved the way for the use of ‘liquid biopsies’ drawn from a blood sample.
Blood samples

IMI planning EUR 45 million Call for proposals on COVID-19

The fast-track, single stage Call will cover therapeutics and diagnostics to tackle the outbreak of the novel coronavirus. IMI plans to launch a Call for proposals on COVID-19, the novel coronavirus that was first reported in China in December 2019 and has since infected over 71 000 people and killed 1 700. The Call, which will be launched in early March, focuses on the development of: therapeutics to address the...


PET scans that show brain changes caused by Alzheimer’s give doctors confidence in diagnosis

Being able to visualise the pathology linked to the disease is a big benefit for diagnosis and patient management. Researchers from an IMI project that set out to get definitive data on the role of amyloid PET scans in Alzheimer’s disease diagnosis are hearing from physicians that being able to visualise the underlying pathology linked to the disease is a big benefit for diagnosis and patient management. The ability to...

Sign up for the IMI2 – Call 20 webinars

IMI2 – Call 20 will be launched in January 2020 and features topics on cancer, tuberculosis, psoriasis, drugs based on proteins, and vaccines. Registration is now open for the IMI2 - Call 20 webinars, which will be held from 22 to 31 January 2020 inclusive. Registration is free but obligatory via the webinar page. There are webinars on all Call topics as well as IMI's rules and procedures and opportunities...

Why it’s so hard to make new antibiotics

There’s no lack of chemicals that can kill bacteria. One of the main reasons there have been so few new antibiotics developed in recent decades – apart from a poor return on investment – is that researchers have run out of ideas on how to outwit the protective mechanisms of Gram-negative bacteria.

For small companies, IMI projects can help tap into new markets

CEO of TRISTAN project partner tells IMI about the opportunities that can open up as a result of getting involved in an IMI project. Karin von Wachenfeldt, Ph. D. is the CEO of Truly Labs, a Swedish SME that carries out preclinical research. Tell us about your company: Truly Labs is a small preclinical CRO (contract research organisation) that provides lab services for drug development. We are based in Lund...

Focus: Antimicrobial resistance 

Antimicrobial resistance is becoming one of the defining problems of our time. As bacteria become resistant to the drugs that are supposed to kill them, scientists, policy makers and the pharma industry are looking at different ways to fix the problem before it’s too late. IMI has invested heavily in AMR research. To date, we have invested almost €800 million on 14 projects. In November, we will be taking a...

New IMI project puts immune cells in the spotlight

EUR 27 million Immune-Image project will advance the use of imaging technologies to track immune cells. Immunotherapies, which harness the immune system to fight disease, are revolutionising the treatment of many cancers and inflammatory diseases. However, while these innovative treatments prove life-saving for some patients, others do not respond to immunotherapies at all, and others experience serious side effects. The 5-year Immune-Image project, which started recently, aims to pioneer the...

Trial of second Ebola vaccine to start in Democratic Republic of the Congo

The trial of the two-dose Ebola vaccine regimen aims to help tackle the current outbreak and strengthen future Ebola epidemic preparedness. An international consortium will soon start a large-scale clinical trial of an Ebola vaccine regimen in the Democratic Republic of the Congo (DRC), which is currently experiencing the second worst Ebola epidemic in history. IMI has contributed significantly to the development of the two-dose vaccine regimen, which is manufactured by the Janssen Pharmaceutical Companies of Johnson & Johnson.

Meet IMI at BIO-Europe 2019

In two weeks’ time, IMI will be in Hamburg for BIO-Europe 2019, which runs from 11 to 13 November. A highlight for IMI will be a session on the morning of 12 November on EU support for small and medium-sized enterprises (SMEs). Among the speakers is IMI’s Magali Poinot, who will explain the benefits for SMEs of participating in IMI projects and show how SMEs can get involved in IMI...

Spotlight on early-career investigators: an interview with Benjamin Falcon

Benjamin Falcon is a scientist in the IMPRiND project, which is investigating the role of misfolded proteins in Alzheimer’s and Parkinson’s diseases. Dr Benjamin Falcon is a postdoctoral scientist at the UK Medical Research Council Laboratory of Molecular Biology, working to untangle the mysteries of neurodegenerative conditions such as Alzheimer’s disease. He completed his PhD with Professor Michel Goedert and has developed an impressive track record of findings that progress...

Good data on medication safety for new and expectant mothers is overdue

A survey intends to get a clear picture of women’s experiences of medicating while pregnant or breast-feeding Video: Caroline Swain was five weeks pregnant when she was diagnosed with breast cancer. Her health providers didn't initially know what treatments she could take. © The Pregnancy and Medicines Initiative The problem Evidence suggests that up to 95% of the five million women who get pregnant in the EU every year will...

Find out about IMI’s future funding opportunities

Cancer, tuberculosis, and psoriasis are among the topics that could be part of our next Call for proposals, IMI2 – Call 20. Also slated for inclusion in the Call are topics on drugs based on proteins, and vaccines.

How do you prepare for a pandemic?

IMI Director Pierre Meulien talks about IMI's reaction to the biggest Ebola outbreak in history and how the world is better prepared for future major epidemics.

Focus on: Ebola

During the month of October we will be taking a look at some of the results of our Ebola-related research projects.